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GaMore than 1 million heart failure hospitalizations occur annually, and congestion is the predominant cause.
Rehospitalizations for recurrent congestion portend poor outcomes independently of age and renal function.
Persistent congestion trumps serum creatinine increases in predicting adverse heart failure outcomes. No
decongestive pharmacological therapy has reduced these harmful consequences. Simpliﬁed ultraﬁltration devices
permit ﬂuid removal in lower-acuity hospital settings, but with conﬂicting results regarding safety and efﬁcacy.
Ultraﬁltration performed at ﬁxed rates after onset of therapy-induced increased serum creatinine was not superior
to standard care and resulted in more complications. In contrast, compared with diuretic agents, some data suggest
that adjustment of ultraﬁltration rates to patients’ vital signs and renal function may be associated with more
effective decongestion and fewer heart failure events. Essential aspects of ultraﬁltration remain poorly deﬁned.
Further research is urgently needed, given the burden of congestion and data suggesting sustained beneﬁts of early
and adjustable ultraﬁltration. (J Am Coll Cardiol 2017;69:2428–45) © 2017 The Authors. Published by Elsevier on
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AND ACRONYM S
NGAL = neutrophil gelatinase-
associated lipocalin
UF = ultraﬁltrationA nnual hospitalizations for heart failureexceed 1 million in both the United Statesand Europe, and more than 90% are due to
symptoms and signs of ﬂuid overload. In addition,
up to 1 in 4 patients (24%) are readmitted within 30
days, and 1 in 2 patients (50%) are readmitted within
6 months (1,2). Recurrent ﬂuid overload in heart fail-
ure has uniformly been associated with worse out-
comes independently of age and renal function (3).
PATHOPHYSIOLOGICAL CONSEQUENCES OF
FLUID OVERLOAD
Compared with normal subjects, asymptomatic
patients with heart failure have decreased sodium
excretion in response to volume expansion (4).
Abnormal ﬂuid handling leads to physiological
abnormalities in multiple organ systems. Increased
myocardial water can lead to ischemia and decreased
contractility in animals and humans (5–8). Deranged
hemodynamics, neurohormonal activation, excessive
tubular sodium reabsorption, inﬂammation, oxida-
tive stress, and nephrotoxic medications are impor-
tant drivers of harmful cardiorenal interactions in
patients with heart failure (8–10).
Elevation of central venous pressure is rapidly
transmitted to the renal veins, causing increased
interstitial and tubular hydrostatic pressure, which
decreases net glomerular ﬁltration (9,11,12). An
increased central venous pressure is independently
associated with renal dysfunction and unfavorable
outcomes in both acute and chronic heart failure
(13,14). Venous congestion itself can produce endo-
thelial activation, up-regulation of inﬂammatory
cytokines, hepatic dysfunction, and intestinal villi
ischemia (15). Bacterial endotoxins can then enter the
circulation, magnifying the inﬂammatory milieu
created by venous congestion and neurohormonal
activity (8).
Three recent studies suggest that failure to
adequately reduce ﬂuid excess in patients with
acutely decompensated heart failure trumps
increases in serum creatinine in predicting poor
outcomes (16). Thus, the foremost goal in managing
acutely decompensated heart failure is to effectively
resolve ﬂuid overload (16). Therefore, if a decrease in
intravascular volume by ﬂuid removal causes small
transient increases in serum creatinine, effectiveresearch grants and consultancy fees from AstraZeneca, Bayer, Bristol-Myer
GlaxoSmithKline, Merck/MSD, Novartis, Servier, Sphingotec, Stealth Peptid
Coridea, LLC. All other authors have reported that they have no relationshi
Manuscript received March 3, 2017; accepted March 7, 2017.decongestion may still be essential to protect
the kidney in the long term (16,17). With-
drawal of diuretic agents in 30 euvolemic
patients with heart failure resulted in in-
creases in urinary levels of kidney injury
molecule-1, which returned to baseline with
resumption of diuretic agents. Thus, in heart failure,
even subclinical ﬂuid overload can be associated with
biological evidence of tubular dysfunction (18). An
unresolved challenge is the ability to discern whether
increase in serum creatinine during ﬂuid removal is
driven primarily by hemodynamic decreases in
glomerular ﬁltration rate or by development of acute
tubular damage, which can progress to chronic kidney
disease (19).
UNRESPONSIVENESS TO DIURETIC AGENTS
IN HEART FAILURE
Diuretic agents remain the cornerstone of therapy for
ﬂuid overload. Although effective early in heart
failure, diuretic agents become increasingly ineffec-
tive with disease progression due to the development
of unresponsiveness in a signiﬁcant subset of patients
(20). Excellent reviews describe the mechanisms
leading to decreased diuretic agent responsiveness
(21). In patients with heart failure, impaired absorp-
tion, decreased renal blood ﬂow, azotemia, and pro-
teinuria all result in reduced levels of active diuretic
agents in the tubular lumen (21). Recently proposed
deﬁnitions of diuretic resistance include persistent
congestion, despite adequate and escalating doses of
diuretic agents equivalent to $80 mg/day furose-
mide; the amount of sodium excretion as a percent-
age of ﬁltered load below 0.2%; and failure to excrete
at least 90 mmol of sodium within 72 h of a 160-mg
twice-daily dose of furosemide. Metrics for diuretic
agent response have also been proposed, including
weight loss per 40 mg of furosemide or equivalent;
net ﬂuid loss per milligram of loop diuretic agent; and
natriuretic response to furosemide as urinary sodium-
to-urinary furosemide ratio (21).
The clinical hallmarks of diuretic agent resistance
are insufﬁcient symptom relief, higher risk of
in-hospital worsening of heart failure, increased
mortality after discharge, and a 3-fold increase in
rehospitalization rates (21,22). Among more than
50,000 patients enrolled in the ADHERE (Acutes Squibb, Boehringer Ingelheim, Cardio3Biosciences,
es, Trevena, and Vifor. Dr. Stough was funded by
ps relevant to the contents of this paper to disclose.
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study, only 33% lost $2.27 kg (5 lbs), and 16% gained
weight during hospitalization. Nearly one-half of
hospitalized patients with heart failure are dis-
charged with residual ﬂuid excess after receiving
conventional diuretic therapies (23). Regardless of
diuretic strategy, 42% of acutely decompensated
heart failure subjects in the DOSE (Diuretic Optimi-
zation Strategies Evaluation) trial reached the com-
posite endpoint of death, rehospitalization, or
emergency department visit at 60 days (24). Vaso-
pressin and adenosine-A1 receptor antagonists,
exogenous natriuretic peptides, and low-dose dopa-
mine, studied as either a complement or a replace-
ment for conventional diuretic therapies, can
decrease ﬂuid overload in the short term but have
failed to improve long-term outcomes (25–27).
Therefore, there is a clear, unmet clinical need for
alternative methods of ﬂuid removal with superior
efﬁcacy in patients with heart failure. One therapy
that might prove successful is extracorporeal ultra-
ﬁltration (UF) (28,29). Greater access to UF has been
facilitated by the development of simpliﬁed devices
that do not require specialized technicians or acute
care settings (Online Table 1) (30).
Over the past 20 years, several small studies have
attempted to deﬁne the physiological rationale for
the clinical beneﬁts of mechanical ﬂuid removal by
UF in heart failure (31–35). However, concerns arose
from reports of treatment-related adverse events (32).
Thus, the principal aims of this paper were to review
the available data for the use of UF in patients with
heart failure, describe the knowledge gaps in this
area, and outline potential future studies to answer
unresolved questions.
PROCESS OF FLUID REMOVAL BY UF,
HEMOFILTERS, PUMPS, AND
VASCULAR ACCESS
Ultraﬁltration consists of the production of plasma
water from whole blood across a semipermeable
membrane (hemoﬁlter) in response to a trans-
membrane pressure gradient (29). The newer,
simpliﬁed UF devices afford the advantages of small
size, portability, low blood ﬂow rates, and an
extracorporeal blood volume below 50 ml. These
devices provide a wide range of UF rates (0 to 500
ml/h) and do not mandate admission to intensive
care units or cannulation of a central vein. The
characteristics of 2 of these devices are shown in
Figure 1. Additional details for hemoﬁlters, pumps,
and vascular access for UF can be found in Online
Appendix in Section 1.0.DIFFERENTIAL CHARACTERISTICS OF
DIURETIC AGENT AND UF-BASED
FLUID REMOVAL
Loop diuretic agents selectively block the Naþ/Kþ/
2Cl cotransporter in the luminal membrane of the
medullary thick ascending loop of Henle. Edema in
patients with heart failure is isotonic, and therefore
normonatremic edematous patients have signiﬁ-
cantly increased total body sodium. Because loop
diuretic agents inhibit sodium reabsorption at a site
in the kidney also critical for water reabsorption, they
generally result in greater loss of water than sodium
and therefore generate hypotonic urine (29).
In contrast, because the ultraﬁltrate is almost
iso-osmotic and isonatremic compared to plasma,
approximately 134 to 138 mmol of sodium are
removed with each liter of ultraﬁltrate (29). Thus, for
any amount of ﬂuid withdrawn, more sodium is likely
to be removed with UF than with diuretic agents (29).
Conversely, with these drugs, changes in intravas-
cular volume are unpredictable. Furthermore, loop
diuretic agents inhibit sodium chloride uptake in the
macula densa, an event that, coupled with
augmented release of prostacyclin, enhances renal
secretion of renin (9,29). These effects augment
neurohormonal activation, which ultimately reduces
diuretic agents’ effectiveness (9). As opposed to the
direct effect of loop diuretic agents on the macula
densa, with UF, neurohormonal activation should
occur only if the ﬂuid removal rate causes intravas-
cular volume depletion by exceeding the plasma
reﬁlling rate (Table 1) (35). This measure of plasma
water transport from the interstitium into the
vasculature during ﬂuid removal varies between
patients depending upon serum albumin concentra-
tion (i.e., serum oncotic pressure) and capillary
permeability.
CLINICAL RESEARCH PRECEDING
CONTROLLED TRIALS OF UF IN
HEART FAILURE
Studies of extracorporeal ﬂuid removal conducted
before the introduction of contemporary UF devices
are summarized in Online Table 2. The key lessons
from these early investigations are that UF can
restore diuretic agent responsiveness, but overly
aggressive ﬂuid removal can convert nonoliguric
renal dysfunction into oliguric failure and dialysis
dependence (34,35). A more detailed description of
the early studies that speciﬁcally evaluated the
mechanisms of action of extracorporeal ﬂuid removal
can be found in Online Appendix in Section 2.0.
FIGURE 1 UF Circuit
(A) The console controls blood removal rates and extracts ultraﬁltrate at a maximum rate set by the clinician. Blood is withdrawn from a vein through the
withdrawal catheter (red) connected by tubing to the blood pump. Blood passes through the withdrawal pressure sensor before entering the blood pump
tubing loop. After exiting the blood pump, blood passes through the air detector and enters the hemoﬁlter (made of a bundle of hollow ﬁbers) through a
port on the bottom, exits through the port at the top of the ﬁlter, and passes through the infusion pressure sensor before returning to the patient (blue).
The ultraﬁltrate passes sequentially through the ultraﬁltrate’s pressure sensor, the pump, and the collecting bag suspended from the weight scale. A
hematocrit sensor is located on the withdrawal line. (B) This UF system requires only a single-lumen, multihole, small (18-gauge) cannula inserted in a
peripheral vein of the arm. A syringe pump drives the blood inside the extracorporeal circuit, which includes 2 check valves that allow the blood to move
from the vein to the ﬁlter, and then returns it to the same vein through alternate ﬂows that can be independent. The priming volume of 50 ml and the
reduced contact surface between blood and tubing set ensure minimal blood loss if circuit clots and for reduced heparin requirements. BD ¼ blood
detector; BLD ¼ blood leak detector; HTC ¼ hematocrit sensor; UF ¼ ultraﬁltration.
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TABLE 1 Comparative Characteristics of Loop Diuretic Agents
and Isolated UF
Loop Diuretic Agents Isolated UF
Direct neurohormonal activation No direct neurohormonal activation
Elimination of hypotonic urine Removal of isotonic plasma water
Unpredictable elimination of
sodium and water
Precise control of rate and amount
of ﬂuid removal
Development of diuretic agent
resistance with prolonged
administration
Restoration of diuretic agent
responsiveness
Risk of hypokalemia and
hypomagnesemia
No effect on plasma concentration
of potassium and magnesium
Peripheral venous access Peripheral or central venous catheter
No need for anticoagulation Need for anticoagulation
No extracorporeal circuit Need for extracorporeal circuit
UF ¼ ultraﬁltration.
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CONTEMPORARY UF SYSTEMS
The SAFE (Simple Access Fluid Extraction) trial
showed that, in 21 congested patients with heart
failure, removal of an average of 2,600 ml of ultra-
ﬁltrate during one 8-h treatment session reduced
weight by an average of 3 kg without changes in heart
rate, blood pressure, serum creatinine concentration,
and electrolytes or the occurrence of major adverse
events (30). Results of 2 additional pilot studies with
this system are summarized in Online Table 3.
The ﬁndings of both studies provided valuable in-
formation. First, the clinical beneﬁts of UF can persist
beyond the index heart failure hospitalization up to
90 days. Second, UF is unlikely to improve outcomes
of patients with end-stage heart failure and should be
used very cautiously in this setting. Third, although
potentially effective in reducing central venous
pressure, aggressive ﬂuid removal in preload-
dependent patients with heart failure, who have low
forward ﬂow as the predominant mechanism for a
reduction in glomerular ﬁltration rate, can rapidly
decrease renal perfusion pressure and cause oliguric
failure, leading to dialysis dependence (36–38). High
pre-treatment intravenous loop diuretic agent doses
may increase the risk of tubular injury when addi-
tional ﬂuid is removed by UF (39).
RANDOMIZED CONTROLLED TRIALS
The randomized controlled trials of UF are summa-
rized in Table 2 and Online Table 4. The RAPID-CHF
(Relief of Acutely Fluid-Overloaded Patients with
Decompensated Congestive Heart Failure) trial was
the ﬁrst randomized study of UF to use the Aquadex
System 100 device (Sunshine Heart, Minneapolis,Minnesota) (40). Although this small study did not
evaluate patients’ outcomes beyond 48 h, it
conﬁrmed that effective ﬂuid removal and clinical
improvement may occur with UF (41).
The physiological fact that reﬁll of the intravas-
cular space from the edematous interstitium de-
creases as ﬂuid is removed led to the hypothesis that
initiation of UF before the plasma reﬁlling rate is
decreased by previous diuretic agent-based therapies
might produce greater beneﬁt than intravenous loop
diuretic agents in unequivocally congested patients
with heart failure. Hence, in the UNLOAD (Ultraﬁl-
tration Versus Intravenous Diuretics Decompensated
Heart Failure) trial, randomization had to occur
within 24 h of hospitalization, and a maximum of 2
intravenous loop diuretic agent doses were permitted
before enrollment (33). Compared with standard care
results, the UF group had greater weight loss and
similar improvement in dyspnea score (the coprimary
endpoints) at 48 h. The percentage of patients with
increases in serum creatinine levels $0.3 mg/dl was
slightly but insigniﬁcantly higher in the UF group
than in the control group at 24 and 48 h (33). Among
UNLOAD patients from a single center, use of iotha-
lamate and para-aminohippurate to measure
glomerular ﬁltration rate and renal plasma ﬂow
showed that UF and furosemide produce similar
changes in these variables (41). There were no
between-group differences in duration of the index
hospitalization, a variable that can be inﬂuenced by
adjustment of oral heart failure therapy before
discharge, performance of additional diagnostic and
therapeutic procedures, treatment of comorbidities,
issues of patients’ placement, and lack of deﬁned
discharge criteria (33,42). In UNLOAD, the 90-day
heart failure events were a pre-speciﬁed secondary
endpoint, and the investigators determined whether
these were related to worsening heart failure or not. It
cannot be said with certainty whether the fewer heart
failure events in 90 days in the UF group compared
with the standard care group were due to differences
in ﬂuid loss, the nature of the ﬂuid removed, or other
factors (33). Because UNLOAD did not have an inde-
pendent clinical events committee (CEC) to adjudi-
cate whether an event was heart failure-related or
not, the possibility of patient or investigator bias
cannot be excluded. A post hoc analysis of UNLOAD
compared the 100 UF patients with 100 usual-care
patients subdivided according to intravenous
diuretic agent strategy (continuous [n ¼ 32] or bolus
[n ¼ 68] administration) (43). Despite removal of the
same amount of ﬂuid by UF and diuretic agent infu-
sion, 90-day heart failure events were fewer in the UF
group (p ¼ 0.016) (43). The simultaneous reduction of
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more effective than removal of hypotonic ﬂuid by
diuretic agents or free water by arginine vasopressin
V2 receptor antagonists (25,43,44). It is also possible
that pre-hospitalization diuretic agent use itself
impairs the natriuretic response to subsequent
intravenous administration of these drugs (21). In
UNLOAD, complications related to UF included
clotting of 5 ﬁlters, 1 catheter infection, and the
requirement for hemodialysis in 1 patient deemed
unresponsive to UF (Table 2) (33).
The UNLOAD trial lacked treatment targets, blood
volume assessments, cost analysis, and adjudication
of events by an independent CEC. Nevertheless,
compared with standard care, UF initiated before the
administration of high-dose intravenous diuretic
agents led to greater ﬂuid loss at 48 h and reduced
90-day heart failure events. In the ULTRADISCO
(Effects of ULTRAﬁltration vs. DIureticS on clinical,
biohumoral and hemodynamic variables in patients
with deCOmpensated heart failure) study, at 36 h,
compared with the diuretic agent group, the UF
patients had greater reduction in body weight, signs
and symptoms of heart failure, aldosterone and
N-terminal pro-B-type natriuretic peptide levels, and
systemic vascular resistance, as well as greater
improvements in objective measures of cardiac per-
formance (45). Albeit very small, this study suggests
that effective ﬂuid removal may be associated with
improved cardiac function (35,45–47).
The CARRESS-HF (Cardiorenal Rescue Study in
Acute Decompensated Heart Failure) trial compared
the effects of UF delivered at a ﬁxed rate of 200 ml/h
with those of stepped pharmacological therapy
inclusive of adjustable doses of intravenous loop
diuretic agents, thiazide diuretic agents, vasodilators,
and inotropes in acutely decompensated patients
with heart failure who had experienced a pre-
randomization increase in serum creatinine
(19,32,48). The primary endpoint of CARRESS-HF was
the bivariate change in serum creatinine and body
weight from baseline to 96 h after randomization (32).
According to the CARRESS-HF design (48), this
primary endpoint assumes that weight loss is a
measurement of effective ﬂuid removal and that an
increase in serum creatinine represents acute tubular
injury. In CARRESS-HF, both groups lost an equiva-
lent amount of weight, but greater increases in serum
creatinine occurred with UF (32). In addition, a higher
percentage of patients in the UF group experienced
serious adverse events (Table 2) (32). However, the
fact that 37 patients (39%) in the UF group received
only diuretic agents or were given these drugs before
the assessment of the primary endpoint at 96 himpairs adjudication of adverse events to one or the
other therapy.
Although in heart failure increases in serum
creatinine ($0.3 mg/dl) have been equated to actual
renal tubular damage, which portends adverse
long-term prognosis, transient increases in serum
creatinine may simply reﬂect a hemodynamically
driven reduction in glomerular ﬁltration rate akin to
that occurring with angiotensin-converting enzyme
inhibitors. Furthermore, recent studies suggest that
transient increases in serum creatinine may reﬂect
more complete decongestion and, instead, forecast
improved post-discharge outcomes (17). Crossover
rates in CARRESS-HF also impaired interpretation of
the ﬁndings of a recent substudy where plasma renin
activity and aldosterone levels were higher in the UF
group than in the stepped pharmacological therapy
group at 96 h. Because neurohormonal levels were
not measured beyond this time point, it remains un-
known whether the observed neurohormonal
changes were transient or sustained (49).
In CARRESS-HF, the rate of ﬂuid removal was
mandated to be 200 ml/h in all UF patients, and
adjustments were left to the discretion of the
investigators, “to address technical problems or
clinical care requirements” (32). A UF rate of 200 ml/h
may be excessive for patients with a lower blood
pressure and greater dependence on preload for he-
modynamic stability (50,51). Clinical experience
shows that, regardless of the method used, removal
of ﬂuid must be tailored to individual patients’ blood
pressure, renal function, urine output, and body
mass. The stepped pharmacological therapy patients
could receive care tailored to their characteristics,
including use of vasoactive drugs, which occurred in
12% of patients in this arm before 96 h (32). Vasoac-
tive agents were prohibited in the UF group, except as
rescue therapy. Interpretation of the results of the
CARRESS-HF trial is also hampered by the fact that
overall outcomes were poor, regardless of ﬂuid
removal strategy: only 10% of the patients had
adequate improvement of signs of ﬂuid overload at
96 h, and more than 30% died or were readmitted for
decompensated heart failure within 60 days (32,52).
In the CUORE (Continuous Ultraﬁltration for
Congestive Heart Failure) trial, UF-treated patients
had a lower incidence of heart failure rehospitaliza-
tions through 1 year (53) than those undergoing
standard care, despite similar weight loss at
discharge. In CUORE, diuretic agent therapy was
continued during UF in the belief that this approach
might help restore diuretic agent responsiveness by
enhancing urinary sodium excretion (53). In previous
studies, diuretic agent therapy was stopped during
TABLE 2 UF Clinical Trials: Overview of Study Designs and Key Findings
Study Name, Publication
Year (Ref. #) Study Group UF Arm Comparison Arm Primary Efﬁcacy Endpoint
RAPID-HF, 2005 (40) N ¼ 40
Hospitalized with HF, 2þ edema
and $1 additional sign of
congestion
Single, 8-h course, median duration
8 h, median volume removed
3,213 ml
Standard HF therapies determined
by treating physician
Weight loss 24 h post-consent
UNLOAD, 2007 (33) N ¼ 200
Hospitalized with HF, $2 signs
of ﬂuid overload
Aquadex System 100†
Mean ﬂuid removal rate 241 ml/h
for 12.3  12 h
Standard care: IV diuretic agents.
For each 24-h period, at least
twice the pre-hospitalization
daily oral dose
Weight loss and dyspnea
assessment at 48 h after
randomization
CARRESS-HF, 2012 (32) N ¼ 188
Hospitalized with HF,$2 signs of
congestion, and recent$0.3
mg/dl sCr increase
Aquadex System 100† at a ﬁxed
rate of 200 ml/h
Median duration 40 h
SPT with intravenous diuretic agents
dosed to maintain urine output
3–5 l/day
Bivariate response of change in
sCr and change in weight
96 h after randomization
CUORE, 2014 (53) N ¼ 56
NYHA III or IV, LVEF#40%,$4 kg
weight gain from peripheral ﬂuid
overload, over 2 months
Dedyca device‡
Mean treatment duration 19  90 h;
volume removed 4,254 4,842 ml
Intravenous diuretic agents
according to guideline
recommendations (standard
care)
HF rehospitalization at 1 yr
AVOID-HF, 2016 (56) N ¼ 224
Hospitalized with HF; $2 criteria
for ﬂuid overload; receiving
daily oral loop diuretic agents
AUF with Aquadex FlexFlow
System§; adjustments per
protocol guidelines on the basis
of vital signs and renal
functionk
Mean ﬂuid removal rate 138  47
ml/h for 80  53 h
ALD with adjustments per
protocol-guidelines on the
basis of vital signs and renal
function¶
Mean furosemide-equivalent dose
271.26  263.06 mg for
100  78 h
Time to ﬁrst HF event (HF
rehospitalization or
unscheduled outpatient or
emergency treatment with
intravenous loop diuretic
agents or UF) within 90 days
of hospital discharge
ULTRADISCO, 2011 (45) N ¼ 30
Hospitalized for HF, $2þ
peripheral edema, $1 other
criteria for volume overload
PRISMA#
Median treatment duration 46 h;
cumulative ﬂuid loss 9.7  2.9 l
Furosemide continuous infusion,
initial dose 250 mg/24 h
Change in hemodynamics
measured by PRAM
*Other than primary endpoint. †CHD solutions, Minneapolis, Minnesota. ‡Dellco, Mirandola, Italy. §Baxter International, Deerﬁeld, Illinois. kSee ﬂow chart in Figure 2. ¶See ﬂow chart in Figure 3. #Hospal
Gambro Dasco, Medolla, Italy.
ALD ¼ adjustable loop diuretic agent; AUF ¼ adjustable ultraﬁltration; CI ¼ conﬁdence interval; CPO ¼ cardiac power output; dP/dtmax ¼maximal rate of rise in left ventricular pressure; HF ¼ heart failure;
HR ¼ hazard ratio; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; PRAM ¼ pressure recording analytical method; SAE ¼ serious adverse event; sCr ¼ serum creatinine;
SPT ¼ stepped pharmacological therapy; UF ¼ ultraﬁltration.
Continued on the next page
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2434extracorporeal ﬂuid removal on the basis of the
hypothesis that UF may give patients a “diuretic
holiday,” during which loop diuretic agent-induced
neurohormonal activation does not occur (33,54,55).
The AVOID-HF (Aquapheresis versus Intravenous
Diuretics and Hospitalization for Heart Failure) trial
tested the hypothesis that patients hospitalized for
heart failure who were treated with adjustable UF
would have a longer time to ﬁrst heart failure event
within 90 days than those receiving adjustable
intravenous loop diuretic agents (56). The AVOID-HF
trial, designed as a multicenter, 1:1 randomized studyof 810 hospitalized patients with heart failure, was
terminated unilaterally and prematurely by the
sponsor (Baxter Healthcare, Deerﬁeld, Illinois) after
enrollment of 224 patients (27.5%). Detailed guide-
lines were provided to the investigators as to how to
adjust both of the therapies in response to patients’
vital signs, renal function, and urine output (Figures 2
and 3) (57). Patients in the adjustable UF group had a
nonstatistically signiﬁcant trend to longer time to
ﬁrst heart failure event than patients in the adjust-
able diuretic agents group (62 vs. 34 days, respec-
tively; p ¼ 0.106). Although the primary outcome did
TABLE 2 Continued
Primary Endpoint Result Reported Clinical Outcomes* Mortality Adverse Events
Weight loss approximately 6.25 kg (UF)
vs. 7 kg (standard care), p ¼ 0.24
Index length of stay: 6 days (UF) vs. 5 days
(standard care); p ¼ NS
Volume removal 24 h after consent:
4,650 ml (UF) vs. 1,838 ml (standard care),
p ¼ 0.001
30 days: 1 (UF) 1 catheter site infection (UF)
Weight loss: 5.0  3.1 (UF) vs. 3.1  3.5
kg (standard care); p ¼ 0.001
Dyspnea score: 5.4  1.1 (UF) vs.
5.2  1.2 (standard care); p ¼ 0.588
90 days: HF rehospitalization:
18% (UF) vs. 32% (standard care), p ¼ 0.022;
HR 0.56; 95% CI: 0.28–0.51; p ¼ 0.04
Unscheduled clinic/emergency visits: 21% (UF)
vs. 44%, p ¼ 0.009
90 days: 9 (9.6%) UF vs.
11 (11.6) standard care
No signiﬁcant between-group
differences, except bleeding (1 UF vs.
7 standard care, p ¼ 0.032).
UF group: 1 catheter infection, 5 ﬁlter
clotting events, 1 patient transitioned
to hemodialysis due to insufﬁcient
response to UF
Mean sCr change: þ0.23  0.70 mg/dl
(UF) vs. 0.04  0.53 mg/dl (SPT)
Mean weight loss: 5.7  3.9 (UF) vs.
5.5  5.1 kg (SPT); p ¼ 0.58
Crossover: STP: 6 patients STP: (6%) also
received UF (2 before 96 h)
UF: 8 patients (9%) received diuretic
agents instead of UF; 28 patients
(30%) also received diuretic agents
before 96 h.
7 days: no difference in death, worsening or
persistent HF, hemodialysis, SAE, or
crossover (23% UF vs. 18% SPT, p ¼ 0.45)
60 days HF hospitalization 26% (UF) vs. 26%
(SPT) p ¼ 0.97
60 day: 17% UF vs.
13% SPT; p ¼ 0.47
60-day SAE:
72% UF vs. 57% SPT; p ¼ 0.03,
attributed to renal failure, bleeding,
or catheter complications
3 (11%) UF vs. 14 (48%) standard care; HR:
0.14; 95% CI: 0.04–0.48; p ¼ 0.002
Length of index hospitalization: 7.4 4.6 (UF) vs.
9.1 1.9 days (standard care), p ¼ 0.23
Combined death or HF rehospitalization
HR for UF vs. standard care 0.35, 95% CI: 0.15–
0.69; p ¼ 0.0035
1 yr:
7 (26%) UF vs. 11 (38%)
standard care; p ¼ 0.33
Premature clotting of ﬁlter in 6 patients
25% AUF vs. 35% ALD (p ¼ 0.11); HR:
0.66; 95% CI: 0.4–1.1
Length of index hospitalization: median 6 (AUF)
vs. 5 (ALD) days, p ¼ 0.106
30-day HF rehospitalizations/days at risk:
11 of 2,876 (AUF) vs. 24 of 2,882 (ALD),
p ¼ 0.06
30-day CV rehospitalizations/days at risk:
17 of 2,882 (AUF) vs. 33 of 2,891 (ALD);
p ¼ 0.037
For both HF and CV events: fewer patients
rehospitalized; fewer number of days
rehospitalized/days at risk
90 days 15% AUF vs. 13%
ALD, p ¼ 0.83
At least 1 SAE: 66% (AUF) vs. 60%
(ALD), p ¼ 0.4
SAEs of special interest: 23% (AUF) vs.
14% (ALD); p ¼ 0.122
Related SAEs: 14.6% (UF) vs. 5.4%
(ALD), p ¼ 0.026
Signiﬁcant between group difference in
% change from baseline in cardiac
index, CPO, dP/dtmax; no signiﬁcant
change in sCr within or between
groups
Signs/symptom score decreased signiﬁcantly in
both groups; no difference between groups
Not reported Not reported
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2435not achieve statistical signiﬁcance, several pre-
speciﬁed secondary endpoints did. In particular, pa-
tients in the adjustable UF group had signiﬁcantly
fewer heart failure and cardiovascular events at 30
days (56). Importantly, these events were adjudicated
by an independent committee blinded to randomized
therapy (56). The ﬁnding of similar renal function
changes in the 2 groups is consistent with that of
UNLOAD (33,56). In AVOID-HF, the average UF rate of
138 ml/h was lower than the ﬁxed 200-ml/h rate of the
CARRESS-HF trial, and therapy was delivered over a
longer period (70 vs. 41 h, respectively) (32,56).
Adjustments of UF rates to individual patients’
hemodynamics and renal function may explain the
lack of differences in serum creatinine betweengroups, despite a larger net ﬂuid loss with UF
(Figures 2 and 3) (56). Although they are detailed, the
therapy guidelines were adopted by the AVOID-HF
investigators, most of whom continued to use them
in their clinical practice. Individualization of ﬂuid
removal rates may explain why the reduction in heart
failure events occurred earlier in AVOID-HF than in
UNLOAD (33,56). Removal of isotonic ﬂuid and
avoidance of renin release by the macula densa may
contribute to the beneﬁt of UF (32,54,55). Restoration
of diuretic agent responsiveness may be a key
mechanism by which UF delays recurrence of heart
failure events (56).
Signiﬁcantly more patients in the UF group than in
the diuretic agents group experienced adverse events
FIGURE 2 Adjustable UF Guidelines Used by the AVOID-HF Investigators
Choose initial UF Rate
SBP 100-120 mm HgSBP < 100 mm Hg
150 cc/h
SBP > 120 mm Hg
250 cc/h200 cc/h
Decrease initial UF rate by 50 cc/hour if ANY of the following are present:
Every 6 hours, evaluate recent BP, HR, UO, net intake/output, sCr
• sCr rise >15% or 0.2 mg/dl compared to
  prior measurement
• Resting SBP decreases >10 mm Hg compared
  to prior 6 h  but remains >80 mm Hg
• UO drops >50% compared to prior 6 h
  but remains >125 cc/6 h
• Resting HR increase >20 bpm compared to
  prior 6 h  but remains <120 bpm
• sCr rise >30% or 0.4 mg/dl compared to
  prior measurement
• Resting SBP decreases >20 mm Hg compared
  to prior 6 h  or >80 mm Hg
• UO <125 cc/6 h
• Resting HR increase >30 bpm compared to
  prior 6 h or >120 bpm
Consider decreasing UF rate by
50 cc/hr and checking STAT sCr
If UF held, re-evaluate after laboratory values are available:
• If hemodynamics are stable and sCr has plateaued, then consider
  re-starting UF at rate 50-100 cc/hr less than previous rate
• If persistent, volume overload present, then consider
      • IV inotropes in patients with LVEF <40% or RV systolic dysfunction
      • Weaning vasodilators, especially in patients with HFpEF
      • RHC
Resolution of congestion (all of the following):
• JVP <8 cm H2O
• No orthopnea
• Trace or no peripheral edema
None of these present Consider completion of UF therapy (See Figure 2, Panel B)
After completion of UF therapy
If satisfactory “dry weight” has been
reached AND sCr is stable:
• Initiate oral loop diuretic therapy with
  goal to keep net even
• GDMT
If sCr, hemodynamics or UO are NOT
stable:
• Hold diuretics until sCr is stable for a
  minimum of 12 h and then:
   • If “dry weight” /adequate decongestion
     has been reached then initiate oral
     diuretics with goal to keep net even
   • If “dry weight” /adequate decongestion
     has NOT been reached then initiate
    IV diuretics
• If elevated sCr or hemodynamic
  instability present, then consider a
  bolus of IV fluid
Any of these
present
Persistent elevation in
sCr >1.0 mg/dl above
baseline at start of
IV diuretic treatment
Best achievable “Dry Weight”
• Evidence of poor tolerance
   of fluid removal
  -AND-
• UF rate <100 cc/hr or
  Net negative < 1 liter/24 h
Persistent
hemodynamic
instability
Strongly consider holding UF and
checking STAT sCr
• RV>LV dysfunction
• sCr increase 0.3 mg/dl above recent baseline
• Baseline sCr >2.0 mg/dl
• History of instability with diuresis or UF in the past
A
B
(A) Guidelines for the adjustment of UF therapy. (B) Guidelines for the completion of ultraﬁltration therapy: 40 mg of furosemide ¼ 1 mg
bumetanide or 10 mg of torsemide (52,53). b.i.d. ¼ twice daily; GDMT ¼ guideline-directed medical therapy; IV ¼ intravenous; JVP ¼ jugular
venous pressure; LV ¼ left ventricular; QD ¼ once daily; RV ¼ right ventricular; SBP ¼ systolic blood pressure; sCr ¼ serum creatinine;
UO ¼ urine output; other abbreviations as in Figure 1.
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2437of special interest (infection requiring intravenous
antibiotics, bleeding requiring transfusion, symp-
tomatic hypotension requiring vasopressor agents
or rapid ﬂuid replacement, a drop in hemoglobin
>3 g/dl, and acute coronary syndrome requiring
intervention [31% vs. 17%, respectively; p ¼ 0.018]).
Serious therapy-related adverse events occurred at
higher rates in the UF group than in the diuretic
agents group (14.6% vs. 5.4%, respectively; p ¼ 0.026)
(56). Although in AVOID-HF, UF-related adverse
events were fewer than in CARRESS-HF, the excess of
therapy-related complications with UF is a serious
concern (32,56). More study of the speciﬁcs of
providing UF are needed to identify strategies aimed
at minimizing access-related and other potentially
preventable complications (32,56). Taken together,
the facts outlined in the preceding text indicate that
the AVOID-HF trial was unable to demonstrate that
adjustable UF is superior to adjustable diuretic agent
therapy. The statistically signiﬁcant secondary out-
comes of fewer 30-day heart failure and cardiovas-
cular events are hypothesis-generating and do not
diminish the critical need for adequately powered
randomized controlled trials comparing the effects of
UF versus diuretic agent-based strategies on both
heart failure morbidity and mortality.
KNOWLEDGE GAPS IN THE USE OF
EXTRACORPOREAL UF IN HEART FAILURE
SELECTION OF POTENTIAL CANDIDATES. The con-
ﬂicting results from UF studies highlight the fact that
patient selection and ﬂuid removal targets are
incompletely understood (32,56). Practice guidelines
suggest that an inadequate response to an initial
dose of an intravenous loop diuretic agent be treated
with an increased dose of the same drug (54,55). If
this intervention is ineffective, invasive hemody-
namic assessment is recommended. Evidence of
persistent ﬂuid excess can then be treated with the
addition of thiazide diuretic agents, aldosterone
antagonists, or continuous intravenous infusion of a
loop diuretic agent. Only if all these measures fail
can UF be considered (58,59). A similar degree of
diuretic agent resistance characterized eligibility for
enrollment in CARRESS-HF (32,33,53,56). In this
trial, the poor outcomes of UF in patients with
the acute cardiorenal syndrome may be partially
related to the lack of therapy adjustment according
to individual patients’ characteristics. In AVOID-HF,
ﬁne-tuning of UF rates in response to vital signs,
renal function, or urine output resulted in greater
net ﬂuid loss and was associated with fewer 30-day
heart failure events without a greater increase inserum creatinine levels than in the adjustable
diuretic agent group (56). These observations un-
derscore the critical need for additional investigation
of UF as both ﬁrst-line and rescue therapies, pro-
vided that UF rates are adjusted in each patient in
response to changes in vital signs and renal function
(32,56).
Due to the potential complications and cost of UF,
it should not be used indiscriminately in decom-
pensated heart failure. For example, in patients with
de novo heart failure or those not receiving daily
diuretic agents, ﬂuid overload can be rapidly elimi-
nated with intravenous diuretic agents, which should
be used in such cases instead of UF. The unanswered
question is which patients who develop heart failure
decompensation despite daily oral diuretic agents
should be considered for UF instead of intravenous
diuretic agents? To date, all studies of UF in patients
with heart failure have relied solely on clinical signs
and symptoms of ﬂuid excess, both as inclusion
criteria and ﬂuid removal targets. This is problematic
due to the poor correlation between clinical assess-
ment and objective measures of increased ﬁlling
pressures (60). A European consensus statement
that graded congestion according to a combination
of clinical and laboratory parameters suggested that
a score of $12, together with urine output of <1,000
ml/24 h, should trigger the use of UF because these
values are indicative of diuretic agent resistance (61).
This recommendation has not been prospectively
validated and relies on the unproven assumption that
the magnitude of ﬂuid excess inﬂuences diuretic
agent responsiveness.
Data from 15 patients with acutely decompensated
heart failure show that urinary sodium concentration
in response to intravenous loop diuretic agents is
highly variable and lower than that in the ultraﬁltrate
(44). The difﬁculty in predicting the natriuretic
response of individual patients to a given dose of
intravenous diuretic agent is underscored by the
absence of a correlation between baseline renal
function and urinary sodium concentration after
furosemide administration (44). The hypothesis that
UF may be especially effective in patients with
urinary sodium concentrations of <100 mEq after a
speciﬁed dose of intravenous diuretic agents should
be tested in randomized trials. A single non-
randomized prospective cohort study showed similar
effects of UF in heart failure with reduced versus
preserved left ventricular ejection fraction (62).
However, because the 2 types of heart failure possess
distinct pathophysiological and clinical characteris-
tics, response to UF should be assessed in controlled
trials.
FIGURE 3 Adjustable Loop Diuretic Agent Guidelines Used by the AVOID-HF Investigators
See table at bottom of figure†
Initial Diuretics Regimen
Continue current
diuretic regimen
At 24 h If Persistent Volume Overload Present
At 48 h If Persistent Volume Overload Present
At 72 h If Persistent Volume Overload Present
Repeat 72 h Step Until Treatment Complete
≤80
81-160
161-240
>240
+ or –
+ or –
+ or –
+ or –
40 mg IV bolus + 5 mg/h
80 mg IV bolus + 10 mg/h
80 mg IV bolus + 20 mg/h
80 mg bolus + 30 mg/h
     0
5 mg metolazone QD
5 mg metolazone BID
5 mg metolazone BID
Loop (mg/day) Thiazide
†Current dose Suggested dose
ThiazideLoop
UO 3- 5 L/dayUO > 5 L/day
Reduce current
diuretic regimen
if desired*
UO < 3 L/day
Advance to next step on table†Continue current
diuretic regimen
UO 3- 5 L/dayUO > 5 L/day
Reduce current
diuretic regimen
if desired*
UO < 3 L/day
Continue current
diuretic regimen
UO 3- 5 L/dayUO > 5 L/day
Reduce current
diuretic regimen
if desired*
UO < 3 L/day
Continue current
diuretic regimen
UO 3- 5 L/dayUO > 5 L/day
Reduce current
diuretic regimen
if desired*
UO < 3 L/day
Advance to next step on table†
and consider:
a.  IV inotropes if SBP <110 mm Hg
and LVEF <40% or RV
systolic dysfunction
b.  NTG or nesiritide if
SBP >120 mm Hg (any LVEF) and
severe symptoms
Advance to next step on table†
and consider:
a.  IV inotropes if SBP <110 mm Hg
and LVEF <40% or RV
systolic dysfunction
b.  NTG or nesiritide if
SBP >120 mm Hg (any LVEF) and
severe symptoms
c.  Right heart catheterization
A
(A) Initiation of loop diuretic agents. *Evaluation of blood pressure, heart rate, urine output, and net intake/output was performed every 6 h; evaluation
of serum chemistries was performed every 12 h. Decreasing or holding the diuretic agent dose may be considered if: 1) serum creatinine rises by 30%
or $0.4 mg/dl (whichever is less) versus previous measurement; 2) resting systolic blood pressure decreases >20 mm Hg compared to previous 6 h
or drops <80 mm Hg; or 3) resting heart rate is >30 beats/min compared to previous 6 h or >120 beats/min. LVEF ¼ left ventricular ejection fraction;
NTG ¼ nitroglycerin; other abbreviations as in Figure 2.
Continued on the next page
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FIGURE 3 Continued
Consider Completion of Therapy if ONE of the following:
Resolution of congestion
(all of the following):
• JVP <8 cm H2O
• No orthopnea
• Trace or no peripheral edema
Best achievable “dry weight”
has been achieved
• Hemodynamic evidence of poor
tolerance of fluid removal by
persistent hemodynamic changes
-AND-
• Net negative <1 l/24 h
Persistent elevation in
sCr >1.0 mg/dL above baseline
at start of IV diuretic treatment
If satisfactory “dry weight” has been reached
AND sCr is stable
• Initiate loop diuretic therapy with goal to keep net even
• GDMT
If sCr, hemodynamics or UO are NOT stable
• Hold diuretics until sCr is stable for a
  minimum of 12 h and then initiate oral
  diuretics as above
• If elevated sCr or hemodynamic instability
  present, then consider a bolus of IV fluid
After Completion of IV Loop Diuretic Therapy
Persistent hemodynamic
instability
B
C
(B) Guidelines for the completion of adjustable loop diuretic agents. (C) Guidelines for management after completion of adjustable loop diuretic agents
(see also references 52 and 53).
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2439FLUID REMOVAL TARGETS AND MONITORING OF UF
THERAPY. One important general recommendation is
that, once an initial UF rate has been chosen, it should
be either maintained or reduced because capillary
reﬁll from the interstitium decreases as ﬂuid is
removed (34). Although the optimal rate and duration
of UF must be individualized, UF rates of >250 ml/h
are not typically recommended (56,57). Patients with
predominantly right-sided heart failure or patients
with heart failure with preserved ejection fraction are
exquisitely susceptible to intravascular volume
depletion and may only tolerate low UF rates (50 to
100 ml/h) (63). In addition, clinical experience
teaches that extracorporeal ﬂuid removal is better
tolerated when conducted with low UF rates over
prolonged periods of time (32).
A frequently used approach is to compare patients’
current weight with that preceding the signs and
symptoms of congestion and to use this “dry weight”
as the target for ﬂuid removal. No consensus exists on
whether removal of only 60% to 80% of excess ﬂuid by
UF and continuation of loop diuretic agents during
therapy results in less hemodynamic instability and
greater urinary sodium excretion (53). Considering the
harmful renal effects of an increased central venouspressure (9,13–15,34,35,64), controlled clinical trials
should determine if ﬂuid removal by UF should be
adjusted to achieve speciﬁc central venous pressure
targets. In lieu of invasive measurements, ultraso-
nography can help estimate central venous pressure
with the assessment of the respiratory excursions of
the diameter of the inferior vena cava (65). Although
ultrasonography is noninvasive and inexpensive, its
reliability depends strictly depends on the operator’s
skill and the patient’s respiratory effort (65).
Studies of implantable hemodynamic monitors
have consistently shown that baseline pulmonary
artery diastolic pressure predicts heart failure events.
Interventions aimed at reducing pulmonary artery
pressures to pre-speciﬁed target ranges have effec-
tively reduced heart failure events without signiﬁcant
renal function changes (66,67). The CardioMEMS
sensor (St. Jude Medical, St. Paul, Minnesota) permits
measurement of pulmonary artery pressures as
frequently as clinically indicated. Therefore, it is
conceivable that, in patients in whom the
CardioMEMS device has been implanted, ﬂuid can be
removed by UF until the target range of pulmonary
artery pressures that effectively reduced heart failure
events has been achieved (66,67).
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The hematocrit is the ratio of the volume occupied by
red blood cells to that of whole blood. Because red
blood cell mass does not change in the short term
unless bleeding occurs, ﬂuctuations in hematocrit
reﬂect changes in intravascular volume (68).
Online hematocrit sensors permit continuous esti-
mation of blood volume changes during UF and can
be programmed to stop ﬂuid removal if the hemato-
crit exceeds a threshold set by the clinician (e.g., 5%
to 7%) and resume therapy when the hematocrit
value falls below the pre-speciﬁed limit, indicating an
adequate reﬁlling of the intravascular volume from
the interstitial space (Online Figure 1) (68).
However, because numerous factors (e.g., change
in body position) can alter hematocrit values,
physical, laboratory, and hemodynamic variables
should be concomitantly assessed to determine the
appropriate UF rates and the amount of ﬂuid that
should be removed (68). Bioimpedance vector
analysis relies on the principle that whole-body
impedance to an alternating current reﬂects total
body water (r ¼ 0.996) (69). Measurements of bio-
impedance vector require 2 pairs of electrodes be
placed on the wrist and ankles and the application of
a 50-kHz alternating microcurrent (CardioEFG, EFG
Diagnostics, Belfast, Northern Ireland) (69). It is
therefore attractive to envision the use of bio-
impedance vector analysis to determine baseline
ﬂuid status and then use of serial measurements to
guide the amount and rate of ﬂuid removal by UF or
diuretic agents. Accuracy of bioimpedance vector
analysis can be reduced by diaphoresis, hirsutism,
incorrect electrode placement, cutaneous alterations,
or improper electrical grounding. Bioimpedance
spectroscopy is also being investigated in patients
with heart failure (70). Unfortunately, no existing
bioimpedance-based method can differentiate intra-
vascular from interstitial extracellular ﬂuid volume, a
distinction that is critical for safe and effective ﬂuid
removal (69,70).
Intrathoracic ﬂuid can also be measured non-
invasively with electromagnetic technology inserted
in a removable vest (Sensible Medical Innovations,
Netanya, Israel). This device, shown in preclinical and
pilot human studies to measure intrathoracic water as
accurately as computed tomography, is being tested
in a prospective, randomized clinical trial
(NCT02448342) (71). The measurement of blood vol-
ume using iodine-131-labeled albumin is accurate, but
the 6 to 9 blood draws needed to create the dilution
curve make it impractical for the serial assessments
needed during ﬂuid removal (72). The lack of optimal
methods for the estimation of blood volume and ﬂuidexcess underscores the critical need for research in
this area.
BIOMARKERS. The use of natriuretic peptides to
assess volume status and guide decongestive thera-
pies cannot be recommended because ﬂuid overload is
not the sole cause of increases in the levels of these
biomarkers (73). The removal of ﬂuid to achieve
pre-speciﬁed natriuretic peptide levels is untested in
acute heart failure. Serum creatinine is the sole
biomarker used to guide ﬂuid removal because of the
belief that its level reﬂects both renal ﬁltration func-
tion and tubular status. However, serum creatinine
was established and validated as a measurement of
renal function only at the point of steady-state
(constant production from the metabolism of muscle
creatine phosphate and unchanging glomerular ﬁltra-
tion and urinary ﬂow to excrete creatinine at a con-
stant rate). Therefore, it is unfortunate that serum
creatinine is the only widely available measurement of
renal function in patients with acute illnesses, such as
acutely decompensated heart failure, where the rates
of creatinine production and excretion may be altered.
Gene expression analysis has shown differences in the
genes expressed in acute kidney injury due to different
processes, even if the magnitude of rise in creatinine is
the same. Conversely, serum creatinine concentration
can be normal with documented tubular injury due to
the delayed achievement of detectable changes of this
analyte (74). Generally, hemodynamically driven
increases in serum creatinine resolve with treatment
in 24 to 72 h, whereas the cellular derangements due to
acute tubular damage, or even necrosis, may last for
weeks (75). Therefore, the duration of the elevation in
serum creatinine has a greater predictive effect on
morbidity and mortality than the extent of this bio-
marker’s elevation (76,77). Indeed, the use of increases
in serum creatinine as an endpoint for acutely
decompensated heart failure trials has been chal-
lenged. Evaluation of the relationship between
changes in serum creatinine and 60-day outcomes in
DOSE subjects revealed that increases in serum creat-
inine from baseline to 72 h (DOSE’s coprimary
endpoint) was associated with lower risk for the com-
posite outcome of death or heart failure events.
Conversely, there was a strong relationship between
improved renal function and unfavorable 60-day
outcomes (78). Thus, serum creatinine changes are
an unreliable surrogate endpoint in trials of ﬂuid
removal therapies. After the discovery by Mishra et al.
(79) of neutrophil gelatinase-associated lipocalin
(NGAL), which is secreted in the urine and the plasma
by a damaged kidney, it was shown that the expres-
sion/secretion of urine NGAL (neutrophil gelatinase-
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2441associated lipocalin) occurred within 3 h of the event
(sepsis, nephrotoxins, obstruction, ischemia); and
that the amount of secreted protein (from 20 ng/ml to
5 mg/ml) was proportional to the severity and time of
resolution of the stimulus. A growing body of evidence
suggests NGAL is not expressed when serum creati-
nine increases due to volume stressors. A systematic
study of thousands of genes encoding for several bio-
markers including NGAL, kidney injury molecule-1,
tissue inhibitor of metalloproteinase-1, and clusterin,
found that these molecules were detectable after a
brief dose of ischemia, yet none of these genes were
expressed after near-fatal volume depletion, despite
the rise in serum creatinine in both models (80).
Although thismethod is not yetwidely available, in the
setting of any method of ﬂuid removal, the levels of
urine NGAL and other biomarkers of tubular injury
could potentially help distinguish a rise in serum
creatinine due to a hemodynamically mediated
decrease in glomerular ﬁltration rate or actual tubular
injury (74). Numerous genes are differentially
expressed depending upon the presence and type of
acute kidney injury. The levels of NGAL rise faster than
those of other indicators of renal injury, making
this biomarker better suited to distinguish between
hemodynamically, versus tubular injury-driven
increases in serum creatinine that may occur during
ﬂuid removal therapies (74,80).
ECONOMIC CONSIDERATIONS. To date, there has
been no prospective evaluation of the cost effective-
ness of UF therapy. The only published retrospective
estimate of UF costs is presented in the Online
Appendix in Section 3.0. Therefore, it is imperative
that future prospective controlled trials include
rigorous cost-beneﬁt analyses.
PROPOSAL FOR FUTURE STUDIES. No studies per-
formed to date have conclusively demonstrated the
superiority of one ﬂuid removal method over another.
It is vital to continue searching for the most effective
and safest method to treat congestion, which worsens
the outcomes of patients with heart failure and cau-
ses unacceptably high hospitalization rates world-
wide. Concerning UF, priority should be given to
mechanistic studies including evaluation of diuretic
agent responsiveness at baseline during and after
ﬂuid removal by using the measurements described
in this review (21). Hemodynamic measurements that
reﬂect ﬂuid status (e.g., central venous pressure and
pulmonary artery diastolic pressure) should also be
performed at baseline and throughout therapy. Spe-
ciﬁc hemodynamic targets indicative of optimal ﬂuid
status should be established in individual patients,
similar to the strategies used to guide medicationadjustment in studies of pulmonary artery pressure
sensors (63). Different UF rates should be tested in
terms of their ability to reach these hemodynamic
targets without causing renal tubular damage, as
detectable by increase in urine levels of biomarkers,
such as NGAL (70,73,76). This will require simulta-
neous measurement of the selected hemodynamic
values and biomarker levels capable of differentiating
rises in serum creatinine due to decreases in
glomerular ﬁltration rate produced by intravascular
ﬂuid removal from those reﬂective of renal injury.
Serial measurements of urine and ultraﬁltrate sodium
content (rather than randomly performed single-spot
measurements) may also help to better characterize
and compare the amount and pattern of sodium
extraction during UF therapy and conventional
diuretic agent-based regimens. This noninvasive,
inexpensive, and readily available test can easily be
incorporated into future investigations. The results of
mechanistic studies are essential to determine how
ﬂuid removal rates and amounts should be adjusted
in individual subjects of future controlled trials
(“precision” ﬂuid removal).
Equally important is the development of vascular
accesses and UF device components that increase the
efﬁciency and safety of the therapy. The device- and
therapy-related adverse events observed in previous
trials should undergo careful re-evaluation to deter-
mine which were preventable or related to operator
experience versus those that were inherent to how
therapy was delivered or was unpredictable
(32,46,47,52).
Only after these issues have been satisfactorily
addressed should a carefully designed, adequately
powered study be considered to prospectively
compare UF with pharmacological ﬂuid removal
therapies. All treatments should be tailored to indi-
vidual patients’ hemodynamic and renal status. In
addition, the study’s follow-up period should be suf-
ﬁciently long to permit the evaluation of morbidity
(rehospitalizations) and mortality. Future trials
should also evaluate whether the greater cost of me-
chanical ﬂuid removal during the index hospitaliza-
tion is offset by the savings resulting from potentially
fewer heart failure events in patients treated with UF.
As the cost of inpatient care is very high, serious
consideration should be given to studies in the
outpatient setting to determine the relative safety
and effectiveness of intermittent pharmacological
and mechanical ﬂuid removal therapies for the pre-
vention rather than the treatment of heart failure
hospitalizations. Intermittent outpatient UF to
restore responsiveness to oral diuretic agents is also a
strategy that deserves investigation. Finally,
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Of the >1 million heart failure hospitalizations in the United States and Europe, 90% are due to signs and symptoms of ﬂuid overload. This enormous worldwide health
care burden is aggravated by the fact that recurrent congestion worsens patients’ outcomes, regardless of age and renal function. Abnormal hemodynamics,
neurohormonal activation, excessive tubular sodium reabsorption, inﬂammation, oxidative stress, and nephrotoxic medications drive the complex interactions between
heart and kidney (cardiorenal syndrome). Loop diuretic agents are used in most congested patients. Due to their mechanism and site of action, loop diuretic agents
lead to the production of hypotonic urine and may contribute to diuretic agent resistance (“braking phenomenon,” distal tubular adaptation, and increased renin
secretion in the macula densa). Increased uremic anions and proteinuria also impair achievement of therapeutic concentrations at their tubular site of action.
Ultraﬁltration is the production of plasma water from whole blood across a hemoﬁlter in response to a transmembrane pressure. Therefore, ultraﬁltration removes
isotonic ﬂuid without direct activation of the renin-angiotensin-aldosterone system, provided that ﬂuid removal rates do not exceed capillary reﬁll. Any method of
ﬂuid removal may cause an increase in serum creatinine. However, in the absence of evidence of renal tubular injury (e.g., augmented urinary concentration of
neutrophil gelatinase-associated lipocalin), this increase represents a physiological decrease in glomerular ﬁltration rate due to decreased intravascular volume from
ﬂuid removal. AVP ¼ arginine vasopressin; GFR ¼ glomerular ﬁltration rate; K ¼ potassium; KIM ¼ kidney injury molecule; Mg ¼ magnesium; NGAL ¼ neutrophil
gelatinase-associated lipocalin; RAAS ¼ renin-angiotensin-aldosterone system; SNS ¼ sympathetic nervous system.
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2442technological advances may permit the development
of “wearable” UF devices capable of delivering indi-
vidualized UF therapy.
CONCLUSIONS
Fluid excess drives most heart failure hospitaliza-
tions. Recurrent hospitalizations are common and
predict unfavorable outcomes. As heart failure pro-
gresses, a signiﬁcant proportion of patients developan inadequate response to diuretic agent therapy.
Additional approaches, such as sequential nephronal
blockade with thiazide diuretic agents or high-dose
aldosterone antagonists, have not been appropri-
ately validated. Other pharmacological therapies
have not improved the outcomes of patients with
heart failure who have ﬂuid overload. Ultraﬁltration
is an attractive alternative therapy because it pre-
dictably removes total body sodium. In future
studies, UF should be adjusted according to the
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2443patient’s hemodynamic and renal proﬁles; and
patient selection, ﬂuid removal amount, duration,
and rate should be guided by objective, complemen-
tary, and informative measurements of ﬂuid overload
and kidney function (Central Illustration). The
urgency of these investigations is underscored by the
alarming prognostic and economic implications of
recurrent heart failure hospitalizations, which remain
unacceptably high with conventional pharmacolog-
ical therapies.ACKNOWLEDGMENT The authors thank Wendy Gat-
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